2.52
0.08 (3.28%)
| Previous Close | 2.44 |
| Open | 2.41 |
| Volume | 114,723 |
| Avg. Volume (3M) | 257,532 |
| Market Cap | 76,173,048 |
| Price / Earnings (TTM) | 28.00 |
| Price / Earnings (Forward) | 16.61 |
| Price / Sales | 0.370 |
| Price / Book | 1.85 |
| 52 Weeks Range | |
| Earnings Date | 29 Apr 2025 |
| Profit Margin | 1.56% |
| Operating Margin (TTM) | -1.23% |
| Diluted EPS (TTM) | 0.090 |
| Quarterly Revenue Growth (YOY) | -2.80% |
| Quarterly Earnings Growth (YOY) | -33.70% |
| Total Debt/Equity (MRQ) | 206.74% |
| Current Ratio (MRQ) | 4.46 |
| Operating Cash Flow (TTM) | 12.72 M |
| Levered Free Cash Flow (TTM) | 15.34 M |
| Return on Assets (TTM) | 2.89% |
| Return on Equity (TTM) | 7.32% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Distribution (US) | Bullish | Bearish |
| Medical Distribution (Global) | Mixed | Bearish | |
| Stock | Zynex, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 1.63 |
|
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others. |
|
| Sector | Healthcare |
| Industry | Medical Distribution |
| Investment Style | Small Core |
| % Held by Insiders | 48.29% |
| % Held by Institutions | 26.73% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 15.00 (HC Wainwright & Co., 495.24%) | Buy |
| Median | 10.25 (306.75%) | |
| Low | 5.50 (RBC Capital, 118.25%) | Hold |
| Average | 10.25 (306.75%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 3.41 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 12 Mar 2025 | 15.00 (495.24%) | Buy | 3.41 |
| RBC Capital | 12 Mar 2025 | 5.50 (118.25%) | Hold | 3.41 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 Apr 2025 | Announcement | SHAREHOLDER DEADLINE: Zynex (ZYXI) Investors Are Reminded of Deadline in Securities Action |
| 22 Apr 2025 | Announcement | Zynex Sets First Quarter 2025 Earnings Call |
| 11 Mar 2025 | Announcement | Zynex Reports Fourth Quarter and Full Year 2024 Financial Results |
| 03 Mar 2025 | Announcement | Zynex Sets Fourth Quarter and Year End 2024 Earnings Call |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |